Skip to main content
MedPathMedPath Home
Clinical Trials/2024-512089-32-00
2024-512089-32-00
Recruiting
Phase 1

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics SA15 sites in 4 countries121 target enrollmentApril 9, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
ADC Therapeutics SA
Enrollment
121
Locations
15
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
euclinicaltrials.eu
Start Date
April 9, 2024
End Date
TBD
Last Updated
last year

Investigators

Responsible Party
Principal Investigator
Principal Investigator

ADC Therapeutics SA

Scientific

ADC Therapeutics SA

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (15)

Loading locations...

Similar Trials

Recruiting
Phase 1
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
2023-506227-29-00AbbVie Deutschland GmbH & Co. KG60
Not yet recruiting
Phase 1
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
2025-523165-19-00BeOne Medicines I GmbH15
Recruiting
Phase 1
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)
2023-507377-17-00Microbiotica Limited27
Active, not recruiting
Phase 1
Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naïvep53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC)MedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-002820-35-NLKartos Therapeutics, Inc.175
Active, not recruiting
Phase 1
Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naïvep53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC)MedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-002820-35-FRKartos Therapeutics, Inc.104